Skip to main content

This job has expired

You will need to login before you can apply for a job.

Research Associate, Discovery Biology (CONTRACT)

Employer
Adicet Bio, Inc.
Location
Menlo Park, California, United States
Start date
Sep 12, 2020

View more

Discipline
Science/R&D, Biology, Research
Required Education
Associate Degree
Position Type
Full time

Job Details

Adicet Bio, Inc. is a biotechnology company founded in 2015 focused on the development of novel off-the-shelf allogeneic gamma delta T cell immune cell therapies for oncology and other indications. resTORbio, Inc. is a public, clinical-stage biopharmaceutical company that has been focused on developing innovative medicines that target the biology of aging to treat aging-related diseases. On April 29, 2020, resTORbio and Adicet announced a reverse merger which is expected to close in the second half of 2020. The resulting publicly-traded company, "Adicet Bio", will focus on progressing Adicet's proprietary gamma delta T cell therapy platform. Adicet expects to initiate clinical development of ADI-001 by the end of 2020 or early 2021. Adicet's second product candidate, ADI-002 subject to the FDA regulatory process for review of INDs, Adicet intends to file an IND and, subject to the FDA regulatory process for review of IND's, initiate a Phase 1 clinical trial in 2021.

Adicet's solid tumor efforts are further complemented by the company's proprietary T cell receptor-like antibody, or TCRL, platform technology, which enables the generation of CARs that recognize tumor antigens inside tumor cells, otherwise known as intracellular proteins. Adicet believes the ability to selectively bind to tumor antigens derived specifically from intracellular proteins is a critical advantage to immunocellular therapy due to the scarcity of tumor-specific surface antigens on solid tumors. Adicet's approach to generating CARs for some product candidates takes advantage of this ability.

RESEARCH ASSOCIATE, DISCOVERY BIOLOGY (CONTRACT)

We are seeking a highly-motivated candidate with a strong basic research background in immunology and cell biology. This position requires expertise in primary cell and tissue culture, and knowledge of general biologic techniques such as transfections, cell based assays and immune cell flow cytometry. The successful candidate will work as a part of a multidisciplinary team, utilizing the latest technologies for cell engineering and contributing to the generation of novel cell based therapeutics for the treatment of cancer.

Job Responsibilities:
Perform research activities including isolation of PBMCs, transduction and expansion of immune cells, and various cell-based and biochemical assays (cytotoxicity, cell phenotyping, ELISA) to support the Adicet Bio Discovery Group. Analyze data and summarize for presentation to the team.

Requirements:
- BS or MS in biological sciences or a related field - 4+ years of relevant academic and industry experience in immunology and/or cell biology

-Hands on experience in primary cell culture and aseptic tissue culture techniques is required. Experience with activation and expansion of T cells is preferred.

- Experience with handling of human biological specimens, particularly blood, isolation of PBMC using density gradient centrifugation (Ficoll).

-Separation of B, T and NK cells by cell enrichment and depletion using magnetic beads or sorting is preferred.

-Experience with multicolor flow cytometry is a plus.

-Experience with cell based assay development is a plus. - Ability to work collaboratively, multitask and meet deadlines in a fast-paced environment.

-Openness to flexible working hours is preferred - Highly motivated, organized and disciplined record keeping - Excellent verbal and written communication skills.

Company

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors.  Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
 
For more information, please visit our website at http://www.adicetbio.com.

Company info
Website
Location
1000 Bridge Parkway
Redwood City
California
94065
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert